219735-87-2

Upstream product

• 219735-86-1 4-(2,4-dichloro-phenyl)-3-nitro-1H-pyridin-2-one 
• 626-03-9 3-deazauracil 
• 89282-12-2 2,4-dihydroxy-3-nitropyridine 
• 219735-85-0 2-benzyloxy-4-(2, 4-dichloro-phenyl)-3-nitro-pyridine 
• 219735-84-9 2-benzyloxy-4-chloro-3-nitropyridine 
• 165547-79-5 2-hydroxy-3-nitro-4-chloropyridine 
• 219735-86-1 4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-ol 

Downstream Products

• 512847-57-3 sec-butyl-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine 
• 512847-52-8 (1-cyclopropyl-ethyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine 
• 512847-55-1 (1-cyclobutyl-ethyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine 
• 512847-56-2 [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-(1-methyl-butyl)-amine 
• 512847-58-4 [4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-(1-ethyl-propyl)-amine 
• 512847-53-9 ((R)-1-Cyclopropyl-propyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine 
• 677742-26-6 C₁₆H₁₇Cl₂N₃O₃ 
• 677742-17-5 C₁₈H₁₉Cl₂N₃O₂ 
• 677742-20-0 C₁₅H₁₅Cl₂N₃O₃ 
• 677742-29-9 C₁₆H₁₇Cl₂N₃O₃ 
• 677742-03-9 [4-(2.4-dichloro-phenyl)-2-nitro-pyridin-2-yl]-isobutyl-amine 
• 677742-12-0 C₁₆H₁₇Cl₂N₃O₂ 
• 512847-54-0 ((S)-1-Cyclopropyl-propyl)-[4-(2,4-dichloro-phenyl)-3-nitro-pyridin-2-yl]-amine 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin- 3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists

Pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones were evaluated as corticotropin-releasing factor-1 receptor antagonists. The synthesis, SAR studies and pharmacokinetic evaluation of these analogs are described herein.

PYRIDINO AND PYRIMIDINO PYRAZINONES FOR TREATMENT OF ANXIETY AND DEPRESSION

The present invention provides compounds of Formula (I): wherein the variables A, B, Ar, R1, R2, and R3 are as defined herein. The compounds of Formula (I) can function as corticotropin releasing factor (CRF) receptor anta

Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands.

A series of high affinity CRF receptor ligands with an imidazo[4,5-b]pyridine core is described. Individual analogues were synthesized and tested in a rat CRF receptor binding assay. The best compounds were further tested in the dog N-in-1 pharmacokinetic model to assess plasma levels at 1mg/kg (po) and in the rat situational anxiety model to assess anxiolytic efficacy at 3mg/kg (po). The structure-activity relationships for good receptor binding affinity are described herein.

Imidazopyridines for the treatment of neurological disorders

Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.